Kinnate Biopharma Inc. announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an oral presentation during the Clinical Trials Mini Symposium Session at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19 in Orlando, Fla. The oral presentation represents the first report of safety and clinical efficacy data from the monotherapy dose escalation portion of KN-8701, an ongoing global Phase 1 clinical trial evaluating exarafenib in patients with BRAF- altered solid tumors and NRAS mutant-positive melanoma. The company also announced that it has initiated enrollment of patients into the monotherapy dose expansion cohorts of KN-8701 and will discuss the expansion strategy, along with results of the AACR presentation and additional pipeline updates.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -0.38% | -.--% | +11.81% |
03/04 | Kinnate Biopharma Inc. Announces Board Resignations | CI |
03/04 | Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+11.81% | 13Cr | |
+54.05% | 5.87TCr | |
-2.02% | 4.13TCr | |
+40.01% | 3.92TCr | |
-10.22% | 2.74TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.9TCr | |
+2.89% | 1.25TCr | |
+22.40% | 1.19TCr | |
+27.49% | 1.21TCr |
- Stock Market
- Equities
- KNTE Stock
- News Kinnate Biopharma Inc.
- Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (Kin-2787), in an Oral Presentation At the AACR 2023